H5P.STU Hikma Pharmaceuticals PLC

- EUR
Market cap
-
P/E
13.4x
P/B
1.87x
ROE
15.5%
Dividend yield
0.42%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is H5P.STU undervalued?

Graham number

The Graham number of Hikma Pharmaceuticals PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hikma Pharmaceuticals PLC fundamental analysis

No fundamental analysis for Hikma Pharmaceuticals PLC yet.

Hikma Pharmaceuticals PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.